Aerie Pharmaceuticals Inc (AERI)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Vicente J. Anido
Employees:
353
7020 KIT CREEK ROAD, SUITE 270, RESEARCH TRIANGLE PARK, NC 27709
919-313-9650

Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It product candidates are Rhopressa and Roclatan. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem and Eric J. Toone on June 22, 2005 and is headquartered in Irvine, CA.

Data derived from most recent annual or quarterly report
Market Cap 318.716 Million Shares Outstanding47.358 Million Avg 30-day Volume 1.062 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-1.75
Price to Revenue9.7705 Debt to Equity-20.8418 EBITDA-135.738 Million
Price to Book Value0.0 Operating Margin-170.1925 Enterprise Value845.867 Million
Current Ratio3.144 EPS Growth0.13 Quick Ratio2.724
1 Yr BETA 0.536 52-week High/Low 21.3 / 6.67 Profit Margin-205.1325
Operating Cash Flow Growth63.1496 Altman Z-Score-3.6328 Free Cash Flow to Firm -43.383 Million
View SEC Filings from AERI instead.

View recent insider trading info

Funds Holding AERI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AERI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KANNAN RAJ CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2021-12-20 2

HOLLANDER DAVID CHIEF R&D OFFICER

  • Officer
31,676 2021-11-11 2

CALABRESE JEFFREY VICE PRESIDENT OF FINANCE

  • Officer
8,019 2021-10-29 1

MCGINLEY KATHLEEN CHRO & VP, CORP SERVICES

  • Officer
24,871 2021-10-06 1

MCGRAW BENJAMIN F III INTERIM EXECUTIVE CHAIR

  • Officer
  • Director
148,475 2021-09-20 2

LAROCCA JOHN GENERAL COUNSEL

  • Officer
39,672 2021-08-14 4

STATEN CHRISTOPHER INTERIM CFO

  • Officer
21,710 2021-08-14 2

GRYSKA DAVID W

  • Director
15,046 2021-06-17 1

MCHUGH JULIE

  • Director
17,650 2021-06-17 1

MCDONNELL PETER J

  • Director
9,550 2021-06-17 1

CAGLE GERALD D.

  • Director
27,850 2021-06-17 1

DU TOIT MICHAEL

  • Director
17,650 2021-06-17 1

CROARKIN RICHARD

  • Director
17,650 2021-06-17 1

ANIDO VICENTE JR CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
243,896 2021-02-23 3

MITRO THOMAS A PRESIDENT AND COO

  • Officer
86,709 2021-02-23 3

RUBINO RICHARD J CHIEF FINANCIAL OFFICER

  • Officer
353,937 2021-02-23 3

KOPCZYNSKI CASEY C. CHIEF SCIENTIFIC OFFICER

  • Officer
264,469 2021-02-23 4

GOLDBERG MURRAY A

  • Director
36,050 2020-05-18 0

FORESITE CAPITAL MANAGEMENT II, LLC

FORESITE CAPITAL FUND II, L.P.

FORESITE CAPITAL FUND III, L.P.

FORESITE CAPITAL FUND IV, L.P.

FORESITE CAPITAL MANAGEMENT III, LLC

FORESITE CAPITAL MANAGEMENT IV, LLC

TANANBAUM JAMES B.

  • 10% Owner
No longer subject to file 2020-02-27 0

FORESITE CAPITAL MANAGEMENT IV, LLC

FORESITE CAPITAL FUND IV, L.P.

TANANBAUM JAMES B.

  • 10% Owner
5,524,591 2019-12-20 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD MGMT III, L.P.

DEERFIELD PRIVATE DESIGN FUND III, L.P.

DEERFIELD PARTNERS, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
5,853,502 2018-07-23 0

FORESITE CAPITAL MANAGEMENT II, LLC

FORESITE CAPITAL FUND II, L.P.

FORESITE CAPITAL MANAGEMENT III, LLC

FORESITE CAPITAL FUND III, L.P.

TANANBAUM JAMES B.

  • 10% Owner
3,643,191 2017-05-26 0

DUYK GEOFFREY M

  • Director
3,400 2017-02-14 0

MEHRA ANAND

  • Director
469,591 2015-04-14 0

LEVY BRIAN CHIEF MEDICAL OFFICER

  • Officer
16,313 2015-02-25 0

CLARUS LIFESCIENCES II, L.P.

CLARUS VENTURES II GP, L.P.

CLARUS VENTURES II, LLC

GALAKATOS NICHOLAS

HENNER DENNIS

LIPTAK ROBERT

SIMON NICHOLAS

STEINMETZ MICHAEL

WHEELER KURT

  • Director
  • 10% Owner
0 2015-01-28 0

TPG GROUP HOLDINGS (SBS) ADVISORS, INC.

BONDERMAN DAVID

COULTER JAMES G

  • FORMER 10% OWNER (2)(3)(4)FORMER 10% OWNER (2)(3)(4)FORMER 10% OWNER (2)(3)(4)
No longer subject to file 2014-11-25 0

ACP IV, L.P.

JANNEY DANIEL

NOHRA GUY P

ACMP IV LLC

  • 10% Owner
No longer subject to file 2014-07-16 0

SOFINNOVA VENTURE PARTNERS VII L P

SOFINNOVA MANAGEMENT VII, L.L.C.

HEALY JAMES

BUATOIS ERIC

POWELL MICHAEL

  • 10% Owner
No longer subject to file 2014-07-09 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KANNAN RAJ - Director - Officer CHIEF EXECUTIVE OFFICER

2021-12-22 20:07:30 -0500 2021-12-20 A 215,783 a 215,783 direct -14.2019 -17.6056 0.0 1 -17.6056 6

KANNAN RAJ - Director - Officer CHIEF EXECUTIVE OFFICER

2021-12-22 20:07:30 -0500 2021-12-20 A 387,169 a 387,169 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
AERIE PHARMACEUTICALS INC AERI 2022-01-21 22:15:03 UTC -0.4071 0.4771 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 21:45:03 UTC -0.4071 0.4771 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 21:15:03 UTC -0.4071 0.4771 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 20:45:03 UTC -0.4151 0.4851 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 20:15:03 UTC -0.4151 0.4851 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 19:45:03 UTC -0.4151 0.4851 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 19:15:03 UTC -0.4151 0.4851 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 18:45:03 UTC -0.4151 0.4851 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 18:15:03 UTC -0.4151 0.4851 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 17:45:03 UTC -0.4151 0.4851 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 17:15:03 UTC -0.4151 0.4851 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 16:45:03 UTC -0.4248 0.4948 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 16:15:03 UTC -0.4248 0.4948 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 15:45:03 UTC -0.4248 0.4948 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 15:15:03 UTC -0.4248 0.4948 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 14:45:03 UTC -0.4248 0.4948 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 14:15:03 UTC -0.4248 0.4948 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 13:45:03 UTC -0.4299 0.4999 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 13:15:03 UTC -0.4299 0.4999 600000
AERIE PHARMACEUTICALS INC AERI 2022-01-21 12:45:03 UTC -0.4299 0.4999 600000

Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Defensive Long Fund AERI -40.0 shares, $-540.0 2020-03-31 N-PORT
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund AERI -112.0 shares, $-2152.64 2019-09-30 N-PORT
Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund AERI -19625.0 shares, $-292608.75 2021-08-31 N-PORT
Federated Hermes Adviser Series- Federated Hermes MDT Market Neutral Fund AERI -8099.0 shares, $-92328.6 2021-09-30 N-PORT
JNL Series Trust- JNL Multi-Manager Alternative Fund AERI -12802.0 shares, $-145942.8 2021-09-30 N-PORT
THE LAZARD FUNDS, INC.- Lazard Enhanced Opportunities Portfolio AERI -3237.0 shares, $-36901.8 2021-09-30 N-PORT

Short Position History (International Only)

Holder Net Short Position Position Date Origin
HBK Investments L.P. Aerie Pharmaceuticals Inc 0.69% 2016-01-11 GERMANY
HBK Investments L.P. Aerie Pharmaceuticals Inc 0.59% 2016-02-18 GERMANY
HBK Investments L.P. Aerie Pharmaceuticals Inc 0.8% 2015-10-26 GERMANY
HBK Investments L.P. Aerie Pharmaceuticals Inc. 0.7% 2015-10-21 GERMANY
HBK Investments L.P. Aerie Pharmaceuticals Inc. 0.51% 2015-10-16 GERMANY
HBK Investments L.P. Aerie Pharmaceuticals Inc 0.79% 2015-12-07 GERMANY

Elevate your investments